Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Operating Expenses (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Operating Expenses for 9 consecutive years, with $137.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 5.79% to $137.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $555.3 million, a 10.65% increase, with the full-year FY2025 number at $555.3 million, up 10.65% from a year prior.
  • Operating Expenses was $137.4 million for Q4 2025 at Denali Therapeutics, roughly flat from $137.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $156.0 million in Q1 2023 to a low of $79.1 million in Q1 2021.
  • A 5-year average of $118.9 million and a median of $119.9 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 43.55% in 2023, then decreased 15.2% in 2024.
  • Denali Therapeutics' Operating Expenses stood at $89.6 million in 2021, then grew by 29.0% to $115.6 million in 2022, then rose by 14.65% to $132.6 million in 2023, then dropped by 2.06% to $129.8 million in 2024, then rose by 5.79% to $137.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Operating Expenses are $137.4 million (Q4 2025), $137.4 million (Q3 2025), and $135.0 million (Q2 2025).